Alzheimer’s disease therapeutics and diagnostics market will reach $8.3 billion in 2017, vis

LONDON - June 26, 2013 - PRLog -- A new report by visiongain predicts the world market for Alzheimer’s disease therapeutics and diagnostics will reach $8.3bn in 2017. That revenue forecast and others appear in Alzheimer’s Disease Therapeutics and Diagnostics: World Market 2013-2023, published in June 2013. Visiongain is a business information provider based in London, UK.

Visiongain forecasts the Alzheimer’s disease (AD) therapeutics and diagnostics market will achieve strong revenue growth to 2023, especially beyond 2017. By 2017, some clinical trials will have finished and innovative products gained regulatory approval. The scope of the field is widening, with many organisations entering and collaborating.

Rodrigo Gutierrez Gamboa, a pharmaceutical industry analyst in visiongain, said: “A high unmet need remains for innovative Alzheimer’s therapies that are able to alter the underlying course of this terminal disease. Several of the leading Alzheimer’s drugs have lost market exclusivity in important regions of the market, leaving the market exposed to intensified generic competition. There is also strong market need for diagnostic technologies for the early detection of AD.

“The R&D pipeline for Alzheimer’s therapies and diagnostics remains strong, with promising candidates, despite the series of high-profile failures in the late stages of clinical development. Beyond 2017, the market will be transformed by the introduction of disease-modifying therapies and innovative diagnostic technologies. The potential of new drugs and diagnostics in this market is enormous, given the high prevalence of AD and limited efficacy and utility of therapies and diagnostic tests currently available.”

Visiongain’s new report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. Research, data and analyses cover activities of Pfizer, Eisai, Forest Laboratories, Lundbeck, Novartis and other pharmaceutical, biotechnology and diagnostics companies.

That study discusses R&D and predicts revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy, India and China.

Alzheimer’s Disease Therapeutics and Diagnostics: World Market 2013-2023 therefore adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Alzheimer's Disease Therapeutics and Diagnostics: World Market 2013-2023 please visit

http://www.visiongain.com/Report/1068/Alzheimer%27s-Disease-Therapeutics-and-Diagnostics-World-Market-2013-2023

For an executive summary please contact: Sara Peerun sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.